Premnath V | Drugs Monitor

(23 June 2020) Tocilizumab- associated with lower mortality, when intubated patients were excluded

June 24, 2020

Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study https://doi.org/10.1093/qjmed/hcaa206 We conducted a in patients with disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary… Continue reading "(23 June 2020) Tocilizumab- associated with lower mortality, when intubated patients were excluded"

(23 June 2020) Tocilizumab- ward based tocilizumab group showed better responses and less infections than ICU tocilizumab group

June 24, 2020

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care https://www.sciencedirect.com/science/article/pii/S1386653220301864?via%3Dihub In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of… Continue reading "(23 June 2020) Tocilizumab- ward based tocilizumab group showed better responses and less infections than ICU tocilizumab group"

(23 June 2020) Chloroquine and Hydroxychloroquine- time to reach viral RNA negativity significantly faster in moderate COVID-19 cases

June 23, 2020

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study https://doi.org/10.1101/2020.06.19.20136093 The clinical utility of chloroquine and hydroxychloroquine in treating COVID-19 was evaluated (ChiCTR2000030054). Forty-eight patients with moderate COVID-19 were randomized to… Continue reading "(23 June 2020) Chloroquine and Hydroxychloroquine- time to reach viral RNA negativity significantly faster in moderate COVID-19 cases"

(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation

June 23, 2020

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1 Reports from the preliminary results of RECOVERY trial [The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936)]for the comparison of dexamethasone 6 mg given once daily for… Continue reading "(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation"

(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers

June 22, 2020

Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes https://doi.org/10.1016/j.chest.2020.06.006 Among 239 patients, median age was 64 years; 36% and 19% were Black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not.… Continue reading "(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers"

(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes

June 22, 2020

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32556143 In an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe Covid-19 in a French university… Continue reading "(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes"

(20 June 2020) Hydroxychloroquine- no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality

June 20, 2020

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France https://doi.org/10.1101/2020.06.16.20132597 In a retrospective study involving large non-selected population of inpatients hospitalized for COVID-19 infection in… Continue reading "(20 June 2020) Hydroxychloroquine- no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality"

(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy

June 19, 2020

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial https://www.sciencedirect.com/science/article/pii/S1567576920312893?via%3Dihub In this prospective non-controlled trial (IRCT20151227025726N12), 20 patients were included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All… Continue reading "(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy"

(16 June 2020) Tocilizumab- Early administration of tocilizumab below FiO2 ≤0.5% significantly more effective

June 17, 2020

Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late https://doi.org/10.1101/2020.06.13.20130088 In a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary… Continue reading "(16 June 2020) Tocilizumab- Early administration of tocilizumab below FiO2 ≤0.5% significantly more effective"

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

June 13, 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. https://doi.org/10.1101/2020.06.05.20123299 The aim of this retrospective intent-to-treat analysis of the hospitalized patients was to compare the rate of clinical improvement between… Continue reading "(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19"

Author: Premnath V